Analysis of predictive biomarker and analysis of correlations between toxicities and SNPs that can be related to pharmacokinetics, in ramucirumab plus paclitaxel therapy for elderly patients with unresectable or recurrent gastric cancer - Analysis of biomarker for ramucirumab plus paclitaxel therapy

Tohoku Clinical Oncology Research and Education Society (T-CORE)0 sites30 target enrollmentApril 1, 2016

Overview

No summary available.

Registry

who.int

Start Date

April 1, 2016

End Date

March 31, 2019

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Tohoku Clinical Oncology Research and Education Society (T-CORE)

•Patients who fulfill the following criteria for exclusion are excluded. 1\) Received taxane\-based regimen. 2\) Synchronous double cancer or past history of other cancer within 5 years, except curable carcinoma in situ and skin cancer. 3\) Active infection and inflammation. 4\) Active hepatitis. 5\) Current or past history within 1 year of serious heart disease that requires hospitalization 6\) Serious complications or severe complications that require hospitalization for therapy, such as gastrointestinal paresthesia, bowel obstruction, interstitial pneumonia, pulmonary fibrosis, uncontrollable hypertension, diabetes mellitus, renal dysfunction, liver dysfunction, and hepatic cirrhosis. 7\) Active gastrointestinal bleeding. 8\) Gastrointestinal perforation or histula, artelial embolism within 6 months or venous thromboembolism within 3 months before registration. 9\) Receiving medications with psychotropic drugs for mental disorders, or having mental disorders that require medications with psychotropic drugs. 10\) Grade 2 or more neuropathy. 11\) Effusion that requires drainage. 12\) Determined to be inappropriate to enter the study by the responsible researcher or contributing researchers, for any other reasons.